

ENHANCING HEALTH THROUGH CANNABIS SCIENCE



TSXV : EMH
OTCQX : EMHTF

Price: \$3.81¹
Market Cap: \$543.47 M¹
Cash: \$52.9 M²
Add. Funding: \$10.8M*
O/S Shares: 136.8 M^{2*}
3 M Avg Vol: 1.36 M³
52W H/L: \$2.04-\$6.06¹

¹19/03/06 ²18/09/30 ³TSX.V + OTCQX

*Recent financing: \$10.8M gross proceeds; 4.0M shares (18/12/07)

Strategic investor, Emerald Health Sciences, owns 28.6% f/d

RECENT ADVANCES

19/03/07 Licensed Endo product wins Taste For Life's 2019 Essentials Supplement Award in the U.S.

19/02/20 Launched Verdélite, 88,000 sf state-of-the-art, fully-integrated indoor facility and Verdélite brand in Québec

19/02/08 JV, Pure Sunfarms (PSF), selected by the Ontario Cannabis Store to supply PSF-branded cannabis products for the non-medical market in the Province of Ontario.

19/02/05 Entered into a license with Indena S.p.A. to use proprietary Phytosome® technology for developing novel cannabinoid-based products.

19/01/29 Licensed Endo product line gains boost with entry into Whole Foods Market stores across US.

EMERALD HEALTH THERAPEUTICS INC.

Leveraging industry-leading life sciences, cannabis and greenhouse growing expertise to achieve highly competitive low cost, value-added cannabis products with potential wellness and medical benefits.

COMPANY HIGHLIGHTS

- One of the industry's most qualified management teams in life sciences, cannabis cultivation & large-scale agri-business. Management & board members have raised over \$1B for development-stage companies and run clinical trials with aggregate budgets exceeding \$1B.
- Entered into a strategic alliance with Factors R&D Technology, Inc, a division of Factors Group of Nutritional Companies Inc, Canada's largest nutritional supplement marketer and manufacturer. The exclusive arrangement provides access to an industrial-scale production facility, capable of processing up to 1M kg of biomass annually and softgel production capacity of up to 600M capsules per year.
- Secured cannabis supply agreements with the provinces of British Columbia, Ontario, Newfoundland and Labrador. Emerald will allocate approximately 13,000 kg of product to the BCLDB. Product quantities for the Ontario Cannabis Retail Corporation and the Newfoundland Labrador Liquor Corporation will be disclosed once details from these provinces are released.
- Purchased 500 acres of harvested hemp chaff in 2018 and up to 1,000 acres in 2019 to 2022 from Emerald Health Hemp, Inc. CBD extract from hemp biomass will be used in Emerald's medical and adult-use products.
- Emerald is advancing its intellectual property portfolio through a recent research agreement with VivaCell Biotechnologies Spain and the filing of 17 provisional US patent applications. Emerald is developing unique cannabinoid formulations and dosage forms for precise and consistent medical-use and improved adult-use products. The Defined Dose™ formulations will be used in smoke, vape and edible Emerald products.



STRATEGIC STEPS TO CREATE PROMINENT INDUSTRY POSITIONING

- Emerald's 50/50 joint venture, Pure Sunfarms, includes decades of large-scale greenhouse growing experience and a 1.1 million square foot licensed commercial production facility. The JV strategically positions Emerald for large-scale, low-cost, high-quality cannabis production, targeting costs below \$1/gram.
- Entered into a 51:49 partnership with San Diego-based Emerald Health Bioceuticals Inc. (EHB) to create Emerald Health Naturals (EHN). Secured exclusive Canadian rights to sell award-winning non-cannabis health products that support the endocannabinoid system through natural health product, grocery, and pharmacy sales channels.
- Acquiring Northern Vine Laboratories, a Licensed Dealer with an R&D facility, allows Emerald to provide analytical testing services, import and export oils and advance product innovation and development plans.
- Launched Verdélite, a Québec-based 88,000 sf purpose-built licensed cannabis production facility with 23 independent growing rooms, 200 cannabis strains and 12 processing and packaging rooms. The facility will include an analytical testing laboratory as well as a research centre for product innovation and extraction technology.



PRODUCTION SCALABILITY

- 1.1M sf greenhouse facility that represents one of Canada’s largest single cannabis growing facilities.
- Option on two additional greenhouses with 3.7M sf.

LOW COST GROWING

- Decades of large-scale greenhouse growing experience plus extensive cannabis growing expertise in optimally configured facility.
- The goal is to produce cannabis at less than \$1/gram.

QUÉBEC: VERDELITE



- Licensed Producer in Saint-Eustache, Québec, near Montréal
- 88,000 sf facility with planned 50,000 sf indoor growing area
- Low-cost energy and water for efficient production

LOOKING AHEAD


The world’s largest legal market for recreational cannabis

On October 17, 2018, the Canadian government legalized cannabis for recreational adult-use. Emerald is expanding capacity to meet the demand and growth of the medicinal and adult-use markets.

Legalization makes Canada the world’s largest federally legal market for recreational cannabis, which Deloitte estimates may exceed \$7.2B in 2019.

The Marijuana Policy Group suggested that 25% of users in the medical use market will generate 85% of the demand. In Colorado, where a fully legal market policy is enforced, 38% of medical users consume cannabis near daily compared to adult use which is 16% near daily.

INTELLECTUAL PROPERTY & PRODUCT INNOVATION: HIGH MARGIN FOCUS



LEADERSHIP

Emerald is distinguished by an established board of directors and management team with extensive experience in pharmaceutical research, product and intellectual property development, large-scale agriculture, and marketing.

Executive Chairman and President, Avtar Dhillon, is a life science entrepreneur with more than 35 years’ experience building public companies through M&A, establishing dominant IP portfolios, and leading innovative scientific and farming enterprises. As a founder/co-founder or lead investor in dozens of life science companies, he has raised over \$1B in public and private financings. Currently, Dr. Dhillon serves as an active board member and chairman for a number of life science and investment companies, and is Chairman of the Cannabis Canada Council.

Emerald’s dynamic team of leaders have decades of experience in clinical research, GMP production practices, quality control, regulatory processes, developing intellectual property, and commercialization of some of the world’s most successful consumer goods on a global scale.

For more information, contact:

INVEST@EMERALDHEALTH.CA
TSXV : EMH | OTCQX : EMHTF

Toll-Free: 1-800-757-3536 IR ext: 5

EMERALDHEALTH.CA